SCHEMBL1200124

SCHEMBL1200124

CC(=O)NC1=CCCc2ccccc21

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.53
RAB9A P51151 4/20 0.53
POLB P06746 1/20 0.46
MAOA P21397 3/20 0.45
CYP1A2 P05177 1/20 0.45
ADRA2A P08913 1/20 0.45
SLC6A2 P23975 1/20 0.45
HTR2C P28335 1/20 0.45
SLC6A4 P31645 1/20 0.45
HTR2B P41595 1/20 0.45
KMT2A Q03164 2/20 0.44
NAPRT Q6XQN6 1/20 0.40
HSD17B10 Q99714 1/20 0.40
PTAFR P25105 1/20 0.39
ALDH1A1 P00352 3/20 0.38
MEN1 O00255 1/20 0.38
MAPT P10636 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
HSP90AA1 P07900 1/20 0.38
HSP90AB1 P08238 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31301103 1.00 NPC1 (0.53) NPC1RAB9APOLBMAOACYP1A2
SCHEMBL19435728 0.90 NPC1 (0.50) NPC1RAB9APOLBMAOACYP1A2
SCHEMBL29139832 0.83 SMN1; SMN2 (0.42) NPC1RAB9AMAOACYP1A2KMT2A
SCHEMBL13114103 0.83 NPC1 (0.39) NPC1RAB9APOLBMAOACYP1A2
SCHEMBL31465075 0.83 NPC1 (0.47) NPC1RAB9APOLBMAOACYP1A2
SCHEMBL5042357 0.83 NPC1 (0.47) NPC1RAB9APOLBMAOACYP1A2
SCHEMBL10041968 0.80 NPC1 (0.42) NPC1RAB9APOLBMAOACYP1A2
SCHEMBL4771351 0.78 CYP1A2 (0.35) NPC1RAB9AMAOACYP1A2KMT2A
SCHEMBL27281859 0.77 CYP1A2 (0.45) NPC1RAB9APOLBCYP1A2KMT2A
SCHEMBL12843388 0.77 CES1 (0.39) NPC1RAB9AMAOACYP1A2ADRA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7884243-B2 reacting 3,4-dihydo-1H-naphtalen-2-one oxime with acetic anhydride in tetrahydrofuran solvent using heterogenous catalyst ( Rh or Ir on Carbon support) in presence of hydrogen to perform hydrogenation/isomerization to form N-(3,4-Dihydro-naphthalen-2-yl)-acetamide ZACH SYSTEM (FR) 2011-02-08 US claimed
CN-1898194-B Novel method for synthesizing alkenyl amide derivatives PPG SIPSY S C A 2010-12-29 CN claimed
EP-1716097-B1 NEW PROCESS FOR THE SYNTHESIS OF ENEAMIDE DERIVATIVES ZACH SYSTEM (FR) 2010-10-13 EP claimed
EP-1897868-A1 N-(3H-inden-1-yl)-acetamide compounds PPG-Sipsy (FR) 2008-03-12 EP claimed
WO-2000038673-A1 COMPOSITIONS CONTAINING AND METHODS OF USING N-ACYL-1H-AMINOINDENES TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) 2000-07-06 WO claimed
CN-113480533-B Preparation method of 3, 4-pyridine diimides derivatives 赣南师范大学 2022-08-02 CN disclosed
CN-113480533-A Preparation method of 3, 4-pyridine diimides derivatives 赣南师范大学 2021-10-08 CN disclosed
US-10011559-B2 Preparation of chiral amides and amines SUNOVION PHARMACEUTICALS INC. (US) 2018-07-03 US disclosed
US-10011559-B2 Preparation of chiral amides and amines SUNOVION PHARMACEUTICALS INC. (US) 2018-07-03 US disclosed
US-20180016224-A1 PREPARATION OF CHIRAL AMIDES AND AMINES SUNOVION PHARMACEUTICALS INC. 2018-01-18 US disclosed
US-20180016224-A1 PREPARATION OF CHIRAL AMIDES AND AMINES SUNOVION PHARMACEUTICALS INC. 2018-01-18 US disclosed
US-20170291885-A1 METHOD FOR PREPARING ENAMIDE COMPOUND AND RUTHENIUM COMPLEX CATALYST USED THEREIN POSTECH ACADEMY-INDUSTRY FOUNDATION (KR) 2017-10-12 US disclosed
US-6737547-B1 Compositions containing and methods of using N-acyl-1H-aminoindenes TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) 2004-05-18 US disclosed
US-6399787-B1 TRANSITION METAL COMPLEX PENN STATE RESEARCH FOUNDATION 2002-06-04 US disclosed
EP-1021397-A4 BENZANTHRONE COMPOUNDS AND ANTIVIRAL USES THEREOF TRIMERIS INC (US) 2000-10-04 EP disclosed
EP-1021397-A1 BENZANTHRONE COMPOUNDS AND ANTIVIRAL USES THEREOF TRIMERIS INC. (US) 2000-07-26 EP disclosed
WO-2000038673-A1 COMPOSITIONS CONTAINING AND METHODS OF USING N-ACYL-1H-AMINOINDENES TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) 2000-07-06 WO disclosed
WO-1999059721-A1 CATALYTIC ASYMMETRIC HYDROGENATION, HYDROFORMYLATION, AND HYDROVINYLATION VIA TRANSITION METAL CATALYSTS WITH PHOSPHINES AND PHOSPHITES THE PENN STATE RESEARCH FOUNDATION (US) 1999-11-25 WO disclosed
WO-1999018065-A1 CHIRAL AMINES CHIROTECH TECHNOLOGY LIMITED (GB) 1999-04-15 WO disclosed
WO-1998039287-A1 BENZANTHRONE COMPOUNDS AND ANTIVIRAL USES THEREOF TRIMERIS, INC. (US) 1998-09-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10011559-B2 Preparation of chiral amides and amines PNMT, ALKBH5, ALKBH2 NPC1 4241/4885RAB9A 4638/4885POLB 1181/4885
US-20180016224-A1 PREPARATION OF CHIRAL AMIDES AND AMINES PNMT, ALKBH2, ALKBH5 NPC1 3994/4885RAB9A 4717/4885POLB 1015/4885
US-20170291885-A1 METHOD FOR PREPARING ENAMIDE COMPOUND AND RUTHENIUM COMPLEX CATALYST USED THEREIN ENY2, ENO1, IDH1 NPC1 4286/4885RAB9A 1323/4885POLB 1854/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.